Management Team


Dr. Allen Davidoff, Ph.D.: President and CEO

Dr. Allen W. Davidoff, Ph.D. (15 years drug development ), Formerly, Chief Scientific officer, VP Product Development and co-founder of Stem Cell Therapeutics Corp. (7 yrs) ( Trillium TRIL:NASDAQ). Prior to Stem Cell Therapeutics Corp., Senior Scientist and Head of Pharmacology at Cardiome Pharma Corp. Allen has a broad range of clinical and regulatory experience. Senior management experience in pharmaceutical R&D including 2 investigational new drug (“IND”) applications or supplemental IND’s, 2 phase I studies (4 multi-country), 7 phase II studies, and 1 NDA. 12 years C- level leadership as Co-founder of Stem Cell Therapeutics Corp (Trillium Therapeutics) – A NASDAQ listed Company and XORTX Therapeutic Corp ( XRX-CSE)

John Meekison, CFO, 

Mr. John Meekison, B.A. is a veteran investment banker with a specialization in both the life sciences and technology sectors at Securities Inc., Diouhy Merchant Group Inc., and Pacific
International Securities Inc. (now PI Financial Corp.). Most recently, John acted as the former CFO and co-founder of iCo Pharma.

Brian Mangal, MsC. BioStatistics: Director Business Development, Product Development

Brian Mangal, MsC. (12 years of clinical development experience) was formerly, Director of Biostatistics for Cardiome Pharma Corp, and responsible for all biometric activities related to the advancement of Cardiome’s clinical programs. Clinical development experience includes design, analysis and reporting on over 50 clinical trials, three FDA submissions, one TPD submission, a successful EMEA submission. Prior to Cardiome, worked on building a CRO – Everest Clinical Research, specializing in dealings with NIH in the US and as a Biostatistician at Pharmacia/Pfizer, worked on the successful sNDA for Linezolid and numerous successful trials with Celecoxib.

Dr. Alan Moore, Founding Board Member, Executive Consultant: Clinical and Regulatory Affairs

Dr. Alan F. Moore, Ph.D. Dr. Moore has extensive clinical development experience and 23 years of senior management experience in pharmaceutical R&D. During his esteemed career, he has completed 11 investigational new drug (“IND”) applications or supplemental IND’s, 15 phase I studies, 12 phase II studies, 7 phase III studies and 2 new drug applications. Most recently CEO of BetaStem Inc.